Oxidative stress and tardive dyskinesia: Pharmacogenetic evidence
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Chul-Hyun | - |
dc.contributor.author | Lee, Heon-Jeong | - |
dc.date.accessioned | 2021-09-05T20:23:23Z | - |
dc.date.available | 2021-09-05T20:23:23Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2013-10-01 | - |
dc.identifier.issn | 0278-5846 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/101916 | - |
dc.description.abstract | Tardive dyskinesia (TD) is a serious adverse effect of long-term antipsychotic use. Because of genetic susceptibility for developing TD and because it is difficult to predict and prevent its development prior to or during the early stages of medication, pharmacogenetic research of TD is important. Additionally, these studies enhance our knowledge of the genetic mechanisms underlying abnormal dyskinetic movements, such as Parkinson's disease. However, the pathophysiology of TD remains unclear. The oxidative stress hypothesis of TD is one of the possible pathophysiologic models for TD. Preclinical and clinical studies of the oxidative stress hypothesis of TD indicate that neurotoxic free radical production is likely a consequence of antipsychotic medication and is related to the occurrence of TD. Several studies on TD have focused on examining the genes involved in oxidative stress. Among them, manganese superoxide dismutase gene Ala-9Val polymorphisms show a relatively consistent association with TD susceptibility, although not all studies support this. Numerous pharmacogenetic studies have found a positive relationship between TD and oxidative stress based on genes involved in the antioxidant defense mechanism, dopamine turnover and metabolism, and other antioxidants such as estrogen and melatonin. However, many of the positive findings have not been replicated. We expect that more research will be needed to address these issues. (C) 2012 Elsevier Inc. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.subject | MANGANESE SUPEROXIDE-DISMUTASE | - |
dc.subject | ABNORMAL INVOLUNTARY MOVEMENTS | - |
dc.subject | GENETIC ASSOCIATION ANALYSIS | - |
dc.subject | DOPAMINE D3 RECEPTOR | - |
dc.subject | VITAMIN-E TREATMENT | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | ALA-9VAL POLYMORPHISM | - |
dc.subject | CHRONIC-SCHIZOPHRENIA | - |
dc.subject | POSSIBLE INVOLVEMENT | - |
dc.subject | FAMILIAL OCCURRENCE | - |
dc.title | Oxidative stress and tardive dyskinesia: Pharmacogenetic evidence | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Heon-Jeong | - |
dc.identifier.doi | 10.1016/j.pnpbp.2012.10.018 | - |
dc.identifier.scopusid | 2-s2.0-84883550642 | - |
dc.identifier.wosid | 000324480900031 | - |
dc.identifier.bibliographicCitation | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, v.46, pp.207 - 213 | - |
dc.relation.isPartOf | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | - |
dc.citation.title | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | - |
dc.citation.volume | 46 | - |
dc.citation.startPage | 207 | - |
dc.citation.endPage | 213 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Neurosciences | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.subject.keywordPlus | MANGANESE SUPEROXIDE-DISMUTASE | - |
dc.subject.keywordPlus | ABNORMAL INVOLUNTARY MOVEMENTS | - |
dc.subject.keywordPlus | GENETIC ASSOCIATION ANALYSIS | - |
dc.subject.keywordPlus | DOPAMINE D3 RECEPTOR | - |
dc.subject.keywordPlus | VITAMIN-E TREATMENT | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | ALA-9VAL POLYMORPHISM | - |
dc.subject.keywordPlus | CHRONIC-SCHIZOPHRENIA | - |
dc.subject.keywordPlus | POSSIBLE INVOLVEMENT | - |
dc.subject.keywordPlus | FAMILIAL OCCURRENCE | - |
dc.subject.keywordAuthor | Oxidative stress | - |
dc.subject.keywordAuthor | Pharmacogenetics | - |
dc.subject.keywordAuthor | Tardive dyskinesia | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.